

Patient Information Handbook

Published by the
Pulmonary Fibrosis Foundation
as a public service to the Pulmonary Fibrosis
Patient Community

“Pulmonary Fibrosis...it takes your breath away”

*There is no cost to the patient for this handbook but donations
will be gladly accepted to help defray the cost of publication.
Send your contribution to the Pulmonary Fibrosis Foundation
at 1440 West Washington Blvd., Chicago, Illinois 60607
312.377.6895*

Acknowledgments

The Pulmonary Fibrosis Foundation would like to thank all those who have contributed to the publication of this extremely valuable Pulmonary Fibrosis Patient Handbook. The major contributor was Suzette McKay, RN, BS, a nurse, a Pulmonary Fibrosis patient and member of the Foundation's Board of Directors and Executive Committee.

Additional contributors include: Dr. Jennifer A. Galvin, member of the Board of Directors. Dr. Galvin participated in Duke University's genetic basis of familial pulmonary fibrosis research study in 2003. Dr. Michael Rosenzweig, President & CEO of the Foundation, one of its cofounders and a pulmonary fibrosis patient.

The Foundation wishes to thank Dr. James Kiley, Director of the Lung Division of the National Heart, Lung and Blood Institute (NHLBI) for his encouragement, suggestions and editorial comments. The NHLBI is one of the Institutes of the National Institutes of Health (NIH). We would also like to thank the American College of Chest Physicians for their assistance in the dissemination of this handbook.

We extend our appreciation to the staff of the Foundation and the members of our Scientific and Medical Advisory Board for reviewing this booklet for medical and scientific accuracy. Finally, we wish to thank all the well wishers for their encouragement and kind words regarding the content and importance of this endeavor.

Table of Contents

Acknowledgments _____	2
Introduction _____	5
Chapter I _____	7
Understanding Pulmonary Fibrosis _____	7
The Lungs _____	7
Chapter II _____	9
What is Pulmonary Fibrosis? _____	9
Interstitial Lung Diseases _____	10
Chapter III _____	11
What are the causes of Pulmonary Fibrosis? _____	11
Chapter IV _____	13
Prevalence of Idiopathic Pulmonary Fibrosis _____	13
Chapter V _____	15
What are the symptoms of IPF? _____	15
Chapter VI _____	17
How is IPF Diagnosed? _____	17
Chest X-Ray _____	17
Pulmonary Function Tests _____	18
Oximetry _____	18
Arterial Blood Gas _____	18
Bronchoscopy _____	18
Bronchoalveolar lavage _____	19
Lung Biopsy _____	19
Exercise Testing _____	19
Chapter VII _____	21
How is IPF Treated? _____	21
Medications _____	21
Oxygen Therapy _____	23
Pulmonary Rehabilitation _____	23
Lung Transplantation _____	23
Chapter VIII _____	25
What is the Prognosis of IPF? _____	25

Table of Contents (continued)

Chapter IX _____	27
What Can You Do? _____	27
Stay in shape _____	27
Stop Tobacco Use _____	28
Learn and Practice Relaxation Techniques _____	28
Join a Support Group _____	29
Participate in Your Health Care _____	29
Explore Supplemental Oxygen Use _____	29
Attitude _____	30
Chapter X _____	31
Going to the Doctor _____	31
Organize Your Medical History _____	31
Chapter XI _____	35
Research/New Treatments _____	35
Chapter XII _____	39
Additional Help _____	39
Appendix – Patient Medical History Form _____	41
Index _____	45

Introduction

Patients often call the Foundation with the news they have just been diagnosed with Pulmonary Fibrosis, feeling frightened, confused and concerned. Family and friends of patients with Pulmonary Fibrosis also call with concerns, struggling to understand how they can support their loved ones. The Foundation created this booklet to provide knowledge, understanding and hope for those afflicted with pulmonary fibrosis. By offering this information, patients and their family or friends can become more familiar with the effects of the disease and bring hope at a time when the road ahead appears to be paved with obstacles.

The information in this handbook is intended as a brief overview of pulmonary fibrosis and is for educational purposes only. It is not intended to be a substitute for professional medical advice. Always consult your own physician or healthcare provider with any questions you may have regarding your specific medical condition. Please know that you can contact the Pulmonary Fibrosis Foundation with any questions or comments. Call 312.377.6895

“Most of the important things in the world have been accomplished by people who have kept on trying when there seemed to be no hope at all.”-Dale Carnegie

“What oxygen is to the lungs, such is hope to the meaning of life.” - Emil Brunner

“Resolve to live as with all your might while you do live, and as you shall wish you had done ten thousand years hence.”
- Jonathan Edwards

The handbook has been published by the Pulmonary Fibrosis Foundation to help the hundreds of thousands of victims of a disease called Pulmonary Fibrosis understand and cope with being stricken by this terminal illness.

Most patients find themselves totally frustrated by the lack of information forthcoming from their physician. Rarely does the doctor take the necessary time to explain to his patient all the details of the disease or help the patient deal with the trauma of being told that he/she has an illness for which there is no cure.

We hope that reading this book will provide the necessary insights to make those choices and adjustments that will improve your quality of life and help you develop a more positive approach and a realistic view of the future you face. Research has shown that an individual's mental attitude can add to or detract from their longevity.

We can look to our future as a challenge to be overcome or give in to despair. As a victim of this disease, I choose to devote my remaining days to being part of the fight to find a cure, secure in the knowledge that this will be achieved. The how and the when will be determined by the medical and scientific communities. What we can do is to provide them with the help and encouragement that will speed that progress. All of us can participate in this common struggle. Please join us so that the day of victory will come sooner.

Michael Rosenzweig, Ph. D.
President
Pulmonary Fibrosis Foundation
1440 West Washington Blvd.
Chicago, Illinois 60607
312.377.6895

Chapter One


Understanding Pulmonary Fibrosis

The Lungs

To understand this disease, it is important to know how normal lungs are built and how they work. This will help you comprehend what happens to the lungs, why people have certain symptoms, and what the patient and the doctor can do to decrease breathlessness.

The body's functions depend upon a steady supply of oxygen. Unfortunately, the body cannot store oxygen so the supply must be fresh and continuous. In addition, waste products such as carbon dioxide must be excreted promptly. If carbon dioxide builds up in the body, it creates an imbalance of acids in the blood. In excess these acids can impair brain and heart functions and cause such symptoms as headache, drowsiness and fatigue.

The lungs are responsible for the exchange of gas. Oxygen goes in, carbon dioxide comes out. Here is how it works. The airways of the lungs look like an upside down tree. The biggest branch is the trachea or windpipe. It branches into smaller bronchial tubes. The very smallest branches are called bronchioles which branch into a cluster of little air sacks called alveoli.



There are about 300 million alveoli in the lungs. Each of these air sacs is surrounded by tiny blood vessels called capillaries and this is where the gas exchange takes place.

Fibrosis or scarring begins in the interstitium. The interstitium is the tissue between the air sacs. Imagine a tub filled with balloons. The balloons are the alveoli, or air sacs. Where the balloons touch each other represents the interstitium. Normally, this is a thin tissue layer with just a few cells in it. When scarring occurs the tissue becomes thicker and the lung becomes stiff, making it is more difficult for oxygen to get into the bloodstream.

While there are many lung diseases that lead to shortness of breath (dyspnea), they generally fall into two main categories: obstructive diseases or restrictive diseases.

Obstructive lung diseases are *airflow* problems. Air can get in but gets trapped and has trouble getting out. Things that limit or obstruct the flow of air include constriction or narrowing of the breathing tubes, increased secretions and swelling of the lining due to inflammation. Cystic Fibrosis, Asthma, Bronchitis, Emphysema and COPD are obstructive diseases.

In contrast, restrictive disease is a *low-air-volume* disorder. Not enough air can get *into* the blood stream due to thickened walls of the air sacs (alveoli). Various Pneumonias and Pulmonary Fibrosis are restrictive diseases.

Chapter Two

What is Pulmonary Fibrosis?

Pulmonary Fibrosis (PF) literally means lung (pulmonary) scarring (fibrosis). The lung scarring occurs in the tissue of the lung called the interstitium, which supports the structures of the lung (air sacs/ alveoli). There are an estimated 130-200 related diseases called Interstitial Lung Disease (ILD) that are similar in characteristics and can result in scarring. PF causes the lung tissue to thicken and become stiff. Scarring inhibits oxygen from entering the blood stream.

The course of PF varies from person to person. For some, the disease may progress slowly and gradually over years, while for others it may progress rapidly. Some people may notice symptoms ranging from moderate to severe. Other people stabilize for a period of time.

Searching for information about this disease can be quite perplexing due to the many terms used to describe Pulmonary Fibrosis. For example, there are many known causes of PF, but when the cause is unknown it is called “idiopathic,” or Idiopathic Pulmonary Fibrosis (IPF). The regions of the fibrotic areas vary from case to case. They affect each person differently and at varying rates.

In the past, Idiopathic Pulmonary Fibrosis (IPF) was a general term used to lump together a variety of processes. However, IPF is also used to describe a distinct pattern of scarring. To make matters more complicated, IPF has *several* names, such as Cryptogenic Fibrosing Alveolitis (CFA) and Usual Interstitial Pneumonia (UIP). The term “usual” was used in the 1960’s to describe the “usual” pattern seen for the interstitial pneumonias. Fortunately, the terminology and classification has undergone modification.

In 1999, an international panel of experts released a consensus statement to provide physicians with practical, up-to-date guidelines for the treatment of Idiopathic Pulmonary Fibrosis (IPF). There are additional Interstitial Lung Diseases (ILD) have no known cause and are also termed “idiopathic”. Some of these include:

- Desquamative Interstitial Lung Disease (DIP). This is relatively rare, affecting twice as many men as women with an average onset age of 42 years. 90% of those affected have a history of smoking. Remission occurs in approximately 20% of patients with smoking cessation. 75% will respond to corticosteroids and complete recovery is possible.
- Respiratory Bronchiolitis Interstitial Lung Disease (RBILB). This is believed to be the same but lesser form of DIP. Average onset age is 36 years. Every person affected is a smoker.
- Lymphangiomyomatosis (LAM). This is a rare ILD that affects only women with an average onset age of 34 years. There are about 800 cases in the United States.
- Acute Interstitial Pneumonia (AIP). This is an acute form of the disease with an abrupt onset and rapid progression to severe shortness of breath and respiratory failure. Many succumb to the disease in 1-2 months.
- Nonspecific Interstitial Pneumonia (NSIP). This is the second most common form of ILD, and is slightly more common in women than men with average onset at 49 years. NSIP is characterized more by inflammation than fibrosis and responds favorably to corticosteroids.
- Idiopathic Pulmonary Fibrosis (IPF). This was initially thought to be a relatively rare disease but is now considered to be one of the most common of the interstitial lung diseases, representing approximately 50-65% all cases. The onset is typically between the ages of 50-70. On average, 2/3 of the patients are in their 60's.

Chapter Three

What are the causes of Pulmonary Fibrosis ?

The process is one of gradual replacement of the lung tissue with fibrosis or scarring, resulting from some type of injury to the lung. In the past, the predominant theory was that this process began with inflammation, which resulted in scar formation. However, it has recently been proposed that fibrosis itself, representing abnormal wound repair, is the primary process rather than inflammation, particularly in IPF.

Fibrosis or scarring sometimes can be linked to particular causes such as prolonged exposure to occupational or environmental contaminants or dusts. This can be due to inorganic dusts such as asbestos, silica, beryllium and hard metal dusts or organic dusts such as bacteria and animal proteins. Some diseases include asbestosis and silicosis. The diseases are often named after the occupations with which they are associated:

- Grain handler's lung
- Mushroom worker's lung
- Bagassosis - Sugar Cane Workers
- Detergent worker's lung
- Maple bark stripper's lung
- Malt worker's lung
- Paprika splitter's lung
- Bird breeder's lung

An additional disease called Hypersensitivity Pneumonitis (or allergic alveolitis) is an allergic disorder caused by the inhalation of organic dusts. In some instances, an acute toxic reaction may occur at the time of exposure to a large dose of spores from a microbe, or within days, weeks or a few months. The acute reaction is generally in the form of bronchitis or asthma. In most cases, a

large cumulative exposure of moderate to high levels of the contaminant is necessary over several years (10-20 years) for Pulmonary Fibrosis to develop. Genetic predisposition is being recognized as playing an important role.

Pulmonary Fibrosis has been associated with autoimmune diseases such as Rheumatoid Arthritis, Scleroderma or Lupus. In addition, lung scarring may be related to upper respiratory infections. Pneumonia and Tuberculosis are examples.

It also has been caused by drugs or certain treatments, such as antibiotics (Nitrofurantoin, Sulfasalazine), antiarrhythmics (Amiodarone, Propranolol), anticonvulsants (Phenytoin), chemotherapeutic agents (Methotrexate, Bleomycin) and therapeutic radiation.

Chapter Four

Prevalence of Idiopathic Pulmonary Fibrosis (IPF)

IPF is the most common form of Interstitial Lung Disease. Below is a summary of the prevalence of the disease:

- The actual incidence is unknown.
- It is estimated that 50,000 new cases are diagnosed annually.
- More than 200,000 people in the United States suffer from this disease.
- There are at least 5,000,000 cases world wide.
- It affects both men and women, with a slightly higher incidence in men.
- The average onset age is 40-70 but the disease can occur at any age.
- Although uncommon, IPF does occur in children and as young as 3 years of age. Interstitial Lung Disease has been diagnosed in children less than one year of age.
- At least forty thousand individuals die from this disease each year.
- The number of new cases of Pulmonary Fibrosis has dramatically increased in recent years. This is primarily due to improved diagnostic procedures.

- IPF has no specific geographical distribution; it is found in equal proportions in urban and rural environments. A history of smoking has been associated with an increased risk of Idiopathic Pulmonary Fibrosis.

Chapter Five

What are the Symptoms of IPF?

Symptoms aren't always present when the disease starts and may not present themselves until the disease has progressed substantially. The main symptom is dyspnea or shortness of breath. Many patients describe it as a feeling of "breathlessness."

Patients often ignore the occasional difficulty with breathing, attributing it to just "getting older" or "being out of shape." As the condition progresses and the damage to the lung becomes more severe, breathlessness may occur with minor physical activity such as showering, getting dressed. Speaking on the phone and eating becomes more difficult and sometimes nearly impossible.

Other symptoms include a dry hacking cough. Some people notice flu-like feelings such as fatigue, weight loss and aching muscles and joints. The patient may also become less able to fight infection. In addition, they may experience frequent tiredness, enlargement and bulb-like development of the fingertips and nails (a condition called clubbing).

The disease varies from person to person. For some, the disease progresses slowly and gradually over months or years while for others there is a rapid progression. For others, it may stabilize for a period of time. The course is generally unpredictable.

Chapter Six

How IPF is diagnosed?

While the family doctor/internist may monitor the course of the illness and treatment, a lung specialist (pulmonologist) should evaluate the patient for confirmation of the diagnosis and treatment guidance.

History and physical exam

The physician will hear ‘crackles’ or Velcro-like sounds with the stethoscope. These sounds are ‘opening’ sounds made by the small airways during inspiration. About 50% of patients with IPF may have “clubbing” of the fingertips. This is a widening of the fingertips due to a lack of oxygen in the blood. This is not specific to IPF and occurs in other lung disorders, heart disease and can also be present from birth.

Chest X-Ray

A routine chest x-ray may be used as a screening test. However, 5-15% of patients with significant scarring will show a normal chest x-ray.

HRCT (CT-SCAN)

High Resolution Computerized Tomography provides sharper and more detailed images than routine chest x-rays.

- “Honeycombing” suggests extensive lung scarring with destruction of the air sacs.
- “Ground-glass opacity” refers to the hazy appearance associated with inflammation.

Pulmonary Function Tests

These are breathing tests that measure the lungs' ability to exchange oxygen and carbon dioxide properly. These tests are usually done in a hospital or clinical laboratory and consist of breathing into a spirometer, and are sometimes done in a "body box" which looks like a glass telephone booth. There are three important components to a Pulmonary Function Test: 1. Spirometry, which determines how well the lungs receive, hold and utilize air; 2. lung volumes, and 3. diffusion capacity, which measures the ability of oxygen to diffuse into the blood stream.

Oximetry

This is a screening test which estimates the amount of oxygen available in the blood. A device is placed on the finger or earlobe. The oximeter transmits light at different wavelengths through small blood vessels. Normal ranges are 95-100% on room air. Oximetry does not measure carbon dioxide levels so a blood gas level measurement may be necessary in some patients.

Arterial Blood Gas

Another method of measuring blood oxygen is by direct analysis of arterial blood, usually obtained from an artery in the wrist. Because arteries contain blood that has just come from the lungs, this provides an accurate measurement of the balance between oxygen and carbon dioxide in the blood.

Bronchoscopy

This involves an examination of the bronchi, or the main airways of the lungs, through the use of a small, flexible tube called a bronchoscope. Bronchoscopy helps to evaluate lung problems or blockages and provides a means to sample tissue or fluids. Unfortunately, the lung tissue samples obtained through bronchoscopy are small and may be inadequate for definitive diagnoses.

Bronchoalveolar lavage (BAL)

BAL is done through the bronchoscope and is a way to remove a tiny sampling of cells from the lower respiratory tract. A very small amount of saline is injected through the bronchoscope and withdrawn, taking with it a tiny sampling of cells from the lower respiratory tract.

Lung Biopsy

Lung biopsy is the most revealing diagnostic step in the evaluation of patients suspected of having Pulmonary Fibrosis. Because there are many diseases that mimic Idiopathic Pulmonary Fibrosis, it is important to get a proper diagnosis, as there are significant differences in treatment and prognosis. This is also the best way to determine how far the disease has progressed and which disease it is. This procedure is invasive with risk factors that should be evaluated and may not be recommended for all individuals.

Exercise testing

Exercise testing is used to measure how well the lungs respond to physical activity. The methods used for exercise testing vary from hospital to hospital, but usually include the use of a stationary bike or treadmill. Blood pressure, EKG and blood oxygen levels (recorded by an electronic device placed on the ear or finger) are monitored during exercise.

Chapter Seven

How is IPF Treated?

Once scar tissue has formed in the lung, it cannot be removed surgically or with medication. Specific treatment will be determined by your physician based on:

- Age, overall health and medical history. Other medical problems that coexist may complicate treatment options.
- Extent of the disease. Because the symptoms often start slowly and progress over a period of time, the disease may be more advanced when diagnosed.
- Your tolerance for specific medications, procedures, or therapies
- Your opinion or preference.

In 1999, the American Thoracic Society recommended treatment, after evidence of impairment, with a combination of corticosteroids and cytotoxic agents such as cyclophosphamide or azathioprine.

For some, medications will stabilize their disease and they may benefit from their continuing usage. Others may find that they can slowly be taken off medication. Unfortunately, a certain percentage of people do not respond to pharmacological therapy. There is no way to predict who will or will not respond to this form of therapy.

Medications

Corticosteroids (Prednisone)

Prednisone is used for suppressing the immune system and inflammation. It mimics the action of cortisol which is produced in the body by the adrenal glands. Prolonged therapy causes the

adrenal glands to stop producing its own cortisol. For this reason when prednisone is discontinued, it must be lowered or tapered gradually to allow time for the adrenal glands to recover. Because Prednisone suppresses the immune system, it can potentially increase the frequency and severity of infections.

The side effects of Prednisone range from mildly annoying to more serious ones. These usually occur with higher doses and prolonged treatment. Not everyone will experience all of these side effects, but they include water retention, and weight gain, puffiness of the face (“moon face”), decreased tolerance to glucose, high blood pressure, muscle weakness, anxiety, depression and sleep disturbance. Cataracts and osteoporosis can occur after prolonged use.

Cyclophosphamide (Cytoxan)

Cytoxan is frequently given in conjunction with Prednisone or may be given alone. While it is usually taken daily by mouth, in some instances it may also be administered intravenously, usually monthly for six months. Cytoxan is an anticancer drug and is used for its immune suppression properties. Because it can lower your white blood count, your physician should monitor your blood count closely during treatment. Cytoxan can also cause bladder irritation due to inflammation (cystitis). Increasing water intake to dilute your urine and urinating more frequently can minimize this side effect. Other side effects include hair loss and nausea.

Azathioprine (Imuran)

Although there have been some successful reports in a small number of people, its effectiveness has not been confirmed.

Other Drugs

In the past, Penicillamine, Chorambucil, and Cholchicine have also been used in a small number of patients with variable results.

Oxygen Therapy

Some patients may require supplemental oxygen particularly when blood oxygen levels become low. This helps to reduce breathlessness, enabling the patient to be more active. Some may need oxygen therapy all the time while others may only need it during sleep and exercise. By testing the level of oxygen in your blood, your physician can tell if you require supplemental oxygen.


Pulmonary Rehabilitation

Pulmonary rehabilitation has become the standard of care for people with chronic lung disease. The aim in pulmonary rehab is to restore the ability to function without extreme breathlessness. These programs offer a variety of services and can be inpatient, outpatient or home/community based. The programs are “multi-disciplinary,” meaning that the team includes nurses, respiratory therapists, physical therapists, social workers, dieticians, etc. The range of services includes: exercise training; breathing exercises and retraining; anxiety, stress and depression management; and nutritional counseling, to name a few.

Lung Transplantation

Pulmonary Fibrosis is the third leading indication for single lung transplantation after Emphysema and Cystic Fibrosis. Transplantation can improve both longevity and the quality of life in properly selected patients, particularly for those under the age of sixty without complicating medical illness. Because the course of PF is unpredictable and available healthy lungs are limited, early referral is crucial. The usual waiting period for donated lungs is approximately two years. Transplantation is not without risk and the patient should discuss all the possible complications with their physician.

Idiopathic Pulmonary Fibrosis: Overall Survival



M Turner-Warwick, *Thorax*. 1980;35:171

Chapter Eight

What is the prognosis of IPF?

IPF is the most common form of Interstitial Lung Disease and in general has a poor prognosis. The average survival rate is roughly 3- 6 years following onset of symptoms (see graph at left). Survival rates are higher when the disease is diagnosed at an earlier stage, at a younger age and in those who have had a beneficial response to corticosteroids. Rapid progression of the disease is associated with cigarette smoking.

The term “average survival rate” is a mathematical one and not medical. There are many individuals who live much longer than six years and others who expire within months after diagnosis. There is a significant correlation between early diagnosis and longevity. It is therefore important to be examined by a competent pulmonologist as soon as the first symptoms appear.

In addition, there are many new developments in both understanding the causes of the disease and the development of effective treatments. Hopefully, these will lead to increased survival time and a better quality of life for those afflicted with Pulmonary Fibrosis.

The most important fact about prognosis is that individuals are unique and people respond differently to treatment. This makes predictions about longevity for any particular person a guessing game. Developing and maintaining a positive attitude will increase survival time for everyone.

Chapter Nine

What you can do?

Stay in shape.

The most damaging consequence of lung disease and its sensation of “breathlessness” is the development of an inactive life style. For many patients, activities of daily living like bathing and dressing can create overwhelming fatigue. Air hunger can create panic attacks, and produce negative psychological effects.

People with chronic respiratory problems sometimes limit their physical activities in an attempt to avoid shortness of breath. In addition, family and friends often warn the patient to “take it easy” thinking that doing otherwise is harmful.

The lack of exercise works against you. Inactivity weakens your muscles and they become less efficient. Deconditioning can make even the simplest daily activities more difficult. Through regular exercise muscles become stronger and more resistant to fatigue. With practice and training you can learn to perform tasks in a more efficient manner. By being more efficient you need less oxygen for the same amount of work. The result is that you may find that you have more energy to accomplish daily tasks and that you are less short of breath. A formal rehabilitation program (Pulmonary Rehab) is preferred because it allows for observation during exercise and the establishment of individualized programs.

Many people breathe inefficiently which causes them to work even harder just to take each breath. During Pulmonary Rehab, breathing techniques are taught which help to improve breathing efficiency and decrease the work of breathing.

Stop Tobacco Use.

Avoiding irritants is a good way to prevent further damage to your lungs. If you are still smoking, the most important thing you can do is to stop. Due to the addictive nature of tobacco, this is can be difficult. Seek the help of your physician to find a smoking cessation class or other beneficial methods to help you.

Second hand smoke can be as harmful as if you were smoking yourself. Family and friends should not smoke around you.

Learn and Practice Relaxation Techniques.

When you are physically and emotionally relaxed, you avoid excessive oxygen consumption caused by tension of overworked muscles.

Learning relaxation techniques can help to manage the panic that often accompanies shortness of breath. Joining a support group and/or seeing a counselor can help you cope with your feelings.

Anxiety and depression are common in people with chronic breathing disorders. These feelings may aggravate the underlining disease. Many fear losing the ability to function and becoming dependent on others. The restriction on activity due to shortness of breath may lead to isolating oneself from family and friends, adding to the depression.

“ I am still determined to be cheerful and happy, in whatever situation I may be; for I have also learned from experience that the greater part of our happiness or misery depends upon our dispositions, and not upon our circumstances.”

-Martha Washington

Join a Support Group.

Just knowing that there is someone “out there” who knows just how you feel is comforting. Share ideas, share fears and share joys. When you give out, you always get back.

Participate in your health care.

Remember you are part of a health care team that includes doctors and nurses. They will be asking you a lot of questions. As a member of that team you have a responsibility to do your part. Be prepared to ask your own questions. Be a participant.

Use of Supplemental Oxygen.

All the body's functions depend upon delivery of a steady supply of oxygen. Pulmonary Fibrosis inhibits the transfer of oxygen into the blood stream. Blood oxygen levels are assessed either by Oximetry, which is a device that can be placed over the finger or ear lobe to measure oxygen saturation, or by obtaining blood from an artery, usually in the wrist, to measure blood gases.

Perhaps your doctor has prescribed supplemental oxygen based on one or both of these tests. A lot of people are fearful that they will become “addicted” to oxygen. This just is not true.

The body requires a steady supply of oxygen and if it is not getting enough, blood vessels may constrict or narrow. The right ventricle of the heart pumps blood returning from the body into the arteries of the lungs. It must work overtime to pump blood through these narrow vessels. This results in an increased strain on the heart which can lead to enlargement of the heart with fluid build up in the liver and legs. This is called Pulmonary Hypertension. The symptoms are shortness of breath and dizziness.

It's hard to tell the difference if you are already short of breath. Supplemental oxygen can reduce this strain, help you feel less breathless, improve your sleep and reduce fatigue. If your doctor has prescribed oxygen, use it.

Attitude

Actively participating in all parts of the management of your disease is greatly enhanced by a positive attitude. You may not be able to control the course of your illness, but you have a choice of attitude every single day.

Do you want to be sad, glad or mad? Pick one. Do you want to be positive or negative? Choose one. A positive attitude may not solve all your problems, but it will certainly make a difference in how you cope with having Pulmonary Fibrosis.

"A strong positive mental attitude will create more miracles than any wonder drug." - Patricia Neal

Chapter Ten

Going to the doctor

Arriving at an accurate diagnosis and the best treatment plan requires time. It's like putting the pieces of a puzzle together. It may require several visits and different tests. You can help your physician know about you. Who's lived in that body all these years? Who knows you better than you?

There will be a lot of health care providers on your team in addition to doctors and nurses. Although you have a health care team, you are an important part of that team. As a team member you have certain responsibilities. You will be asked a lot of questions. As a patient, it is sometimes difficult to remember who you talked to and what you said. The first visit to a new physician may produce a lot of anxiety. It's easy to forget something important if you are a little nervous. Try to relax and remember that your teams' purpose is to provide you with the best care possible.

Organize your medical history prior to your visit

Put it in writing, keep a copy for yourself and update as necessary.

1. Frequently the question you are asked are: Why are you here today? What is the reason for this visit?
 - a. Start with your symptoms. What are they? Be specific. For example:
 - “I have a cough.”
 - “I'm short of breath.”
 - b. How long have you had the symptoms?
 - c. What aggravates them?
 - d. Does anything relieve them?

2. List all medication:
 - a. Include prescription and over the counter medications such as vitamins, minerals and herbs.
 - b. Include the reason and the how often you take them. Many medicines have multiple purposes. Don't assume "he/she knows" the reason you take each medicine.
 - c. Don't rely on others to remember this information for you. What if the other person is not available, in an accident or in the hospital? Then what?
 - d. It is sometimes helpful to take all medication(s) with you to show your physician so if there are any questions regarding dosage there will be no confusion.
3. Take a small notebook with you to all visits:
 - a. When you ask a question write down the answer. That way, when you get home you won't be frustrated trying to remember what the doctor said to you.
 - b. Before each visit, write down questions you want to ask.
 - c. Ask about your test results and write down the answer. Never assume that everything is "O.K." if you do not hear from the doctor's office
4. Don't stop prescribed medications on your own, even if your symptoms have stopped.

A sample 3- page medical history form is available for use in the appendix of this document. This does not replace the history taken by your health care team, but is a useful tool. It provides a guide for questions and answers by your team. It helps you to remember important dates, events and symptoms. It's good to keep a copy with you and update as necessary. It is also a good idea to give a copy to a family member as well. If you are ill or have an emergency, your family members will be able to provide correct information regarding your history and medications.

1. List your past and current medical conditions. List medical problems such as diabetes, high blood pressure, heart attacks and cancer. Include information about how long you've had these problems.
2. List all surgeries. Be sure to include dates. List everything. Don't assume it's not important because "it has nothing to do with my lungs."

Chapter Eleven

Research/New Treatments/Antifibrotic IPF Therapies

We apologize for the technical language in which this chapter is written. It was necessary to do so to maintain the scientific accuracy of the information that is included. Please bring this chapter to your physician and allow him/her to discuss with you the concepts and material contained here.

N-Acetylcysteine is a chemical, commonly called NAC, produced by the body that enhances the production of the enzyme glutathione, a powerful antioxidant. NAC helps boost the immune system. NAC is used as a mucus dissolving agent to help break up the thick mucus often present in people suffering from chronic respiratory ailments. In Europe, a large scale clinical trial of NAC therapy with 150 IPF patients is currently underway.

Pirfenidone is an orally active small molecule drug that appears to inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Cytokines are small secreted proteins which mediate and regulate immunity and inflammation. They must be produced de novo in response to an immune stimulus. They act by binding to specific membrane receptors, which then signal the cell via second messengers, often tyrosine kinases, to alter its behavior (gene expression). Responses to cytokines include increasing or decreasing expression of membrane proteins (including cytokine receptors), proliferation, and secretion of effector molecules.

Anti Transforming Growth Factor (TGF-B) therapies TGF-b likely plays a crucial role in the progression of fibrotic disease. It is secreted by activated epithelial cells, macrophages, and endothe-

lial cells in an inactive form bound to latency-associated peptide. TGF- β is released from latency-associated peptide after it is bound by thrombospondin-1 found in platelet granules or the α V β 6 integrin expressed on epithelial cells. The active molecule stimulates fibroblast chemotaxis, differentiation, and collagen synthesis. Pulmonary levels of TGF- β are elevated after intratracheal instillation of Bleomycin in mice and rats. Fibrosis in this model is significantly attenuated by administration of anti-bodies or soluble TGF- β receptor. TGF- β messenger RNA (mRNA) and protein production is greatly increased in epithelial cells and macrophages of patients with IPF, as are circulating levels of TGF- β . While no therapy currently available specifically targets TGF- β , *Interferon gamma* (IFN γ) treatment may lower TGF- β expression in the lungs of IPF patients with an associated improvement in pulmonary function.

ACE Inhibitors. ACE stands for angiotensin converting enzyme. GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases, including Emphysema. ACE inhibitors have been successful in a small group of patients.

Prostaglandin E2. Abbreviated PGE-2, A chemical released by blood vessel walls in response to infection or inflammation. The enzyme mPGES-1 is involved in the production of PGE-2. Other adverse prognostic factors include male gender, advanced disease, and possibly increased release of PGE-2, from macrophages (Schwartz et al. 1994)

Leukotriene receptor antagonist. The action of leukotriene can be blocked through either of two specific mechanisms: 1) inhibition of leukotriene production and, 2) antagonism of leukotriene binding to cellular receptors.

Endothelin receptor antagonist. An endothelin-receptor antagonist, Bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting that endothelin may contribute to elevated blood pressure in such patients.

Anti Tumor Necrosis Factor (TNF) - alpha Therapies. Another mediator likely to play an important role in IPF is TNF- α . TNF- α levels are increased in BAL fluid from IPF patients, and TNF- α production is increased in alveolar macrophages from patients with IPF. TNF- α production is also up-regulated in pulmonary epithelia from IPF patients. It is mitogenic and chemotactic for fibroblasts, but in contrast with TGF- β , suppresses collagen synthesis. In response to transient pulmonary overexpression of TNF- α using an adenoviral vector, mice demonstrate a significant inflammatory and fibrotic response. However, in this model, TGF- β production is stimulated soon after infection with the TNF-expressing adenovirus. Thus, it is unclear whether TNF- α acts independently to stimulate fibrosis or merely through its ability to induce TGF- β production. These data are not definitive but suggest a role for TNF- α in the pathogenesis of IPF. As antagonists of TNF- α activity are already in use in the treatment of several inflammatory disorders (e.g., Crohn's disease, rheumatoid arthritis), consideration should be given to testing what effect blocking TNF- α function would have in IPF. In a small series of patients with IPF, such treatment was associated with clinical improvement.

Relaxin. Relaxin inhibits TGF- β -induced collagen synthesis by fibroblasts and directly stimulates fibroblasts to produce collagenase. Recombinant human Relaxin was recently used in a randomized, double-blind, placebo-controlled trial in the treatment of scleroderma. When given as a continuous subcutaneous infusion, Relaxin was associated with a moderate improvement in skin thickness at the lower of two doses tested. Forced vital capacity

and diffusion capacity were not significantly altered by Relaxin therapy but, notably, patients with “severe” IPF were excluded from the study. The most common adverse effects were a mild drop in hemoglobin level, irritation at the infusion site, menorrhagia, and metrorrhagia. Additional studies are needed to determine if Relaxin may be useful in the treatment of IPF.

Lovastatin. Lovastatin is one of a group of drugs called statins, which are normally used to lower cholesterol. It is currently being tested for the treatment of Pulmonary Fibrosis. During these tests it was found to potently inhibited granulation tissue formation in vivo. In addition to its proapoptotic effect on fibroblasts, Lovastatin most likely blocked formation of granulation tissue by targeting the action of multiple cellular functions. Several steps in the growth factor signaling cascade are modulated by Lovastatin, including growth factor receptor activity and signal transduction events.

However, the work reported here represents the first steps in demonstrating that lovastatin and other HMG-CoA reductase inhibitors can be effective in modulating fibroproliferation. We view these studies as promising because they support a therapeutic option that is safe and readily available for further preclinical and clinical testing in a class of diseases for which few if any effective alternatives exist.

There are many other ongoing research studies. Various government agencies maintain databases on clinical trials. While ClinicalTrials.gov (www.clinicaltrials.gov) contains the most comprehensive listing of NIH supported clinical trials available, not all trials are in the database. Another source of information is the National Heart, Lung and Blood Institute: www.nhlbi.nih.gov. For additional details, please visit the Pulmonary Fibrosis Foundation’s website at: www.pulmonaryfibrosis.org

Chapter Twelve

Additional help

You may want to consider joining the on-line support group at:
[http://health.groups.yaho.com/group/pff](http://health.groups.yahoo.com/group/pff)

Contact the Pulmonary Fibrosis Foundation, Jennifer Bulandr, Director of Media and Community Relations at (312) 377- 6895 regarding starting a support group in your area.

There are a variety of websites that contain information on Pulmonary Fibrosis. Some of the information may be valuable while others are unreliable or misleading. In your search you will find more information by typing in Interstitial Lung Disease.

The Simmons Center for Interstitial Lung Disease
<http://ipf.upmc.com>

University of Iowa Health Book
www.vh.org

The National Jewish Medical and Research Center
www.njc.org

Duke University
This site is devoted to Familial Idiopathic Pulmonary Fibrosis (FIPF). This is the same as IPF but is defined as a primary family unit with 2 or more persons who have IPF.
www.fpf.duke.edu

National Institutes of Health
www.nih.gov

The National Library of Medicine
www.nlm.nih.gov

Various government agencies maintain databases on clinical trials. The NIH through the National Library of Medicine has developed a web site to provide patients, family members and physicians with current information about clinical research.
www.clinicaltrials.gov

The National Home Oxygen Patients Association was established in the late 1990's to give oxygen users the information necessary to lead productive lives.
www.homeoxygen.org

Traveling with Oxygen
www.breathineasy.com

Appendix – Patient Medical History Form

NAME: _____ AGE: _____
PHYSICIAN: _____ DATE: _____

1. What is the reason for your visit today? What are your symptoms?

2. How long have you had these symptoms?

3. Has the respiratory problem: improved worsened
 stayed the same

Comments:

4. On a scale of 0-5 (0 is not at all, 5 is intolerable), how badly does your problem bother you? _____

5. Does anything make the problem better or worse?

6. Have you changed your lifestyle or activities because of your respiratory problem?

Yes No

If yes, explain

7. MEDICAL HISTORY (check all that apply and indicate how long it has been a problem)

- Diabetes _____
- Arthritis _____
- Headache/Migraines _____
- Heart problems _____
- Weakness in legs _____
- Epilepsy/Seizures _____
- High blood pressure _____
- Neurologic Problems _____
- Elevated Cholesterol _____
- Bleeding tendencies _____
- Depression _____
- Kidney Problems _____
- Thyroid _____
- Difficulty walking _____
- Dizziness _____
- Heart attack _____
- Back problems _____
- Reflux _____
- Stroke _____
- Anxiety _____
- Ulcers _____

Other medical conditions or hospitalizations not listed here:

8. SURGICAL HISTORY

type of surgery _____ approximate date _____

9. List Current Prescription Medicines and Over-The-Counter Medicines:

Name of Medication	Dosage	Reason for Use
--------------------	--------	----------------

11. ALLERGIES:

12. TOBACCO USE:

Never smoked

Yes Packs per day _____ Number of years _____

Do not now but used to smoke

Packs per day _____ Number of years _____

Date stopped _____

Additional comments:

Index

A

abnormal wound repair 11
accurate diagnosis 31
ACE Inhibitors 36
Additional help 39
Air hunger 27
alveoli 8
arterial blood 18
asthma 8
Attitude 30
autoimmune diseases 12
average survival rate 25

B

bleomycin 35
Blood oxygen levels 29
blood vessels 8
breathing tests 18
breathlessness 15, 27
Bronchoscopy 18
Bronchoalveolar lavage (BAL) 19

C

capillaries 8
carbon dioxide 7
Cataracts 22
cigarette smoking 25
COPD 8
Corticosteroids 21
corticosteroids 25
cystic fibrosis 8
Cytoxan 22

D

diagnosis 17
dry hacking cough 15
dyspnea 8, 15

E

emphysema 8
Endothelin receptor antagonist 36
environmental contaminants 11
Exercise testing 19

F

fibrosis 8

G

Genetic Predisposition 12
Ground-glass opacity 17

H

High Resolution Computerized Tomography 17
Honeycombing 17

I

idiopathic 9
Idiopathic Pulmonary Fibrosis 9
improved diagnostic procedures 13
Imuran 22
inflammation 11, 36
interstitial lung disease 9

L

Leukotriene receptor antagonist 36
longevity 25
Lovastatin 38
Lung Transplantation 23
Lung Biopsy 19

Lupus 12

M

medical history 31

N

National Library of Medicine 40

O

obstructive diseases 8

osteoporosis 22

Oximetry 18

oxygen 7

oxygen saturation 29

P

Pirfenidone 35

positive attitude 25

Prednisone 21

prevalence of IPF 13

prognosis 25

pulmonary fibrosis 8, 9

Pulmonary Rehab 27

Pulmonary Rehabilitation 23

R

rehabilitation 27

relaxation techniques 28

Relaxin 37

restrictive diseases 8

Rheumatoid Arthritis 12

right ventricle 29

S

scarring 11

Scleroderma 12

Second hand smoke 28
shortness of breath 15
Specific treatment 21
Spirometry 18
supplemental oxygen 23
Support Group 29
Survival rates 25
Symptoms 15

T

Traveling with Oxygen 40
treatment guidance 17

U

Understanding IPF 7
Usual Interstitial Pneumonia 9

X

x-ray 17

